Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody

Nimisha Deb, Michael Goris, Kirk Trisler, Sherry Fowler, Jeannette Saal, Shoucheng Ning, Mark Becker, Carol Marquez, Susan Knox

Research output: Contribution to journalArticlepeer-review

128 Scopus citations


A Phase I dose-escalation study using 90Y-CYT-356 monoclonal antibody was performed in 12 patients with hormone-refractory prostate carcinoma. Biodistribution studies using 111In-CYT-356 were performed 1 week before 90Y-CYT-356 administration. Of the 12 patients, 58% had at least one site of disease imaged after administration of 111In-CYT-356. The dose of 90Y ranged from 1.83-12 mCi/m2. Both 111In and 90Y-CYT-356 were tolerated well, without significant nonhematological toxicity. Myelosuppression was the dose-limiting toxicity and occurred at dose levels of 4.5-12 mCi/m2. Of the patients receiving ≤9 mCi/m2, 55% had grade 1 or 2 leukopenia and/or thrombocytopenia. Two of three patients treated with 12 mCi/m2 experienced grade 3 thrombocytopenia and leukopenia. One patient treated with 12 mCi/m2 had grade 4 neutropenia. The maximum tolerated dose of 90Y-CYT-356 was 9 mCi/m2. Only one patient developed a human anti-mouse antibody 4 weeks after treatment. No patient attained a complete or partial response based on prostate-specific antigen and/or radiological criteria. Three patients had transient subjective improvement in the symptomatology of their disease. In addition, patients treated with 12 mCi/m2 of 90Y-CYT-356 had a slightly longer freedom from disease progression than patients treated with doses of 90Y-CYT-356 ≤9 mCi/m2.

Original languageEnglish (US)
Pages (from-to)1289-1297
Number of pages9
JournalClinical Cancer Research
Issue number8
StatePublished - Aug 1996

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody'. Together they form a unique fingerprint.

Cite this